XOMA - XOMA acquires royalty and milestone interest in Checkmate's Vidutolimod from Kuros Biosciences

XOMA Corporation (XOMA) has acquired the royalty interest position Kuros Biosciences (CSBTF) holds in Checkmate Pharmaceuticals’ vidutolimod (CMP-001).Kuros will receive an initial upfront payment of $7M, may receive up to $24M in pre-commercial milestones from Checkmate and is eligible to receive up to $142.5M in sales milestones from Xoma.The U.S. Food and Drug Administration has granted Fast Track designation to vidutolimod for the treatment of certain types of metastatic or unresectable melanoma and an Orphan Drug designation for Stages IIb - IV melanoma. XOMA could receive up to $25M in pre-commercial milestones associated with the Kuros/Checkmate license agreement.

For further details see:

XOMA acquires royalty and milestone interest in Checkmate’s Vidutolimod from Kuros Biosciences